Globus Medical Inc. Class A Common Stock vs J M Smucker Co — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while J M Smucker Co trades at $121.85 (market cap $12.96B). The key difference: J M Smucker Co is the larger of the two by market cap, and J M Smucker Co pays a 3.69% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and J M Smucker Co for 74 Days on average.
| GMED | SJM | |
|---|---|---|
Market Cap | $10.25B | $12.96B |
Volume | 1,108,124 | 1,039,289 |
Sector | Health | Consumer Staples |
52-Week High | $96.82 | $132.34 |
52-Week Low | $58.33 | $89.53 |
Typical Hold Time | 0 Days | 74 Days |
Enterprise Value | $9.76B | $19.81B |
Dividend Yield | — | 3.69% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
SJM trades at $121.84, up 1.52% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $3.24, beating expectations, and raised FY27 guidance. However, 2025 fundamentals show a net loss of $1.23B and elevated P/E of 56.7, while analyst consensus is a Buy with a $138.23 price target.
Outlook is mixed; robust growth in segments like Uncrustables and raised guidance support upside, but high valuation, volatile profitability, and debt levels pose risks. The stock offers a dividend yield but faces competitive and margin pressures in the consumer staples sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →